Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
1998
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
2001
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
1999
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
2002
Automated Assay for HER-2/neu in Serum
2000
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
2000
Herceptin: mechanisms of action and resistance
2005
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
1998
Magnetic resonance molecular imaging of the HER-2/neu receptor.
2003
ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency
2000
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer
1997
Serial serum c-erbB-2 levels in patients with breast carcinoma
1996
The DNA-damage response in human biology and disease
2009 StandoutNature
Prognostic Factors in Breast Cancer
2000
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
2000 Standout
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
2004
Inflammation and cancer
2002 StandoutNature
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
mTOR Signaling in Growth Control and Disease
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Transcriptional Complementarity in Breast Cancer: Application to Detection of Circulating Tumor Cells
2001
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
2003
Tumor angiogenesis: past, present and the near future
2000
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
2005 StandoutNature
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Genetic instabilities in human cancers
1998 StandoutNature
Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway
2002 StandoutNobel
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
1997
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
1998
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Telomere Dysfunction Increases Mutation Rate and Genomic Instability
2001 StandoutNobel
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
2005
Novel Recurrent Genetic Imbalances in Human Hepatocellular Carcinoma Cell Lines Identified by Comparative Genomic Hybridization
1999
Wnt/β-Catenin Signaling and Disease
2012 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Molecular Determinants of Occult Metastatic Tumor Cells in Bone Marrow
2001
Osteoclast differentiation and activation
2003 StandoutNature
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
2000 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells
2003
The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability
2001 StandoutNobel
The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer
2000
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
2010 StandoutNature
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1996
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
Role of YAP/TAZ in mechanotransduction
2011 StandoutNature
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
The cancer genome
2009 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2000 Standout
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
2001
Life with Oxygen
2007 StandoutScienceNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
2001
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
2001 StandoutNobel
The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women
2001
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
2006
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Immune recognition and tumor protection
2002
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
2000
Works of A. Lipton being referenced
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
2003
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
1998